<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">systhiper-183</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group></article-categories><title-group><article-title>Содержание мочевой кислоты и ее роль на ранних стадиях гипертонической болезни</article-title><trans-title-group xml:lang="en"><trans-title>The level of uric acid and its role at early stages of essential hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ощепкова</surname><given-names>Е. В.</given-names></name></name-alternatives><email xlink:type="simple">arthyplab@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дмитриев</surname><given-names>В. А.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Половиткина</surname><given-names>О. В.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Титов</surname><given-names>В. Н.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ФГУ РКНПК Федерального агентства по высокотехнологичной медицинской помощи, Москва НИИ кардиологии им. А.Л.Мясникова, Москва</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>6</volume><issue>2</issue><fpage>51</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ощепкова Е.В., Дмитриев В.А., Половиткина О.В., Титов В.Н., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Ощепкова Е.В., Дмитриев В.А., Половиткина О.В., Титов В.Н.</copyright-holder><copyright-holder xml:lang="en">Ощепкова Е.В., Дмитриев В.А., Половиткина О.В., Титов В.Н.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/183">https://www.syst-hypertension.ru/jour/article/view/183</self-uri><abstract/><trans-abstract xml:lang="en"/><kwd-group xml:lang="ru"><kwd>гипертоническая болезнь</kwd><kwd>мочевая кислота сыворотки крови и мочи</kwd><kwd>неспецифичное воспаление</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout: new insights into pathogenesis and treatment. Bulletin of the NYU Hospital for joint diseases 2007; 65 (3): 215-21.</mixed-citation><mixed-citation xml:lang="en">Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout: new insights into pathogenesis and treatment. Bulletin of the NYU Hospital for joint diseases 2007; 65 (3): 215-21.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and coronary heart disease. Ann Intern Med 1951; 34: 1421-31.</mixed-citation><mixed-citation xml:lang="en">Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and coronary heart disease. Ann Intern Med 1951; 34: 1421-31.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Brand FN, McGee DL, Kannel WB et al. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol 1985; 121: 11-8.</mixed-citation><mixed-citation xml:lang="en">Brand FN, McGee DL, Kannel WB et al. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol 1985; 121: 11-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Freedman DS, Williamson DF, Gunter EW et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-Up study. Am J Epidemiol 1985; 141: 637-44.</mixed-citation><mixed-citation xml:lang="en">Freedman DS, Williamson DF, Gunter EW et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-Up study. Am J Epidemiol 1985; 141: 637-44.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bengtsson C, Lapidus L, Stendahl C et al. Hyperuricaemia and risk of cardiovascular disease and overall. A 12-year follow-up of participants in the population study of women in Gotheburg, Sweden. Acta Med Scand 1988; 224: 549-55.</mixed-citation><mixed-citation xml:lang="en">Bengtsson C, Lapidus L, Stendahl C et al. Hyperuricaemia and risk of cardiovascular disease and overall. A 12-year follow-up of participants in the population study of women in Gotheburg, Sweden. Acta Med Scand 1988; 224: 549-55.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Reunanen A, Takkunen H, Knekt P et al. Hyperuricemia as a risk factor for cardiovascular mortality 1982; 668: 49-59.</mixed-citation><mixed-citation xml:lang="en">Reunanen A, Takkunen H, Knekt P et al. Hyperuricemia as a risk factor for cardiovascular mortality 1982; 668: 49-59.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Alderman MH. Podagra, uric acid, and cardiovascular disease. Circulation 2007; 116: 880-3.</mixed-citation><mixed-citation xml:lang="en">Alderman MH. Podagra, uric acid, and cardiovascular disease. Circulation 2007; 116: 880-3.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sundstro..m J, Sulliva L, D`Agostino RB et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33.</mixed-citation><mixed-citation xml:lang="en">Sundstro..m J, Sulliva L, D`Agostino RB et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Perlstein TS, Gumeniak O, Williams GH et al. Uric Acid and the development of hypertension. The Normative Ageing Study. Hypertension 2006; 48: 1031-6.</mixed-citation><mixed-citation xml:lang="en">Perlstein TS, Gumeniak O, Williams GH et al. Uric Acid and the development of hypertension. The Normative Ageing Study. Hypertension 2006; 48: 1031-6.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mellen PB, Bleyer AJ, Erlinger TP et al. Serum uric acid predicts incident hypertension in a biethnic cohort. The atherosclerosis risk in communities study. Hypertension 2006; 48: 1037-42.</mixed-citation><mixed-citation xml:lang="en">Mellen PB, Bleyer AJ, Erlinger TP et al. Serum uric acid predicts incident hypertension in a biethnic cohort. The atherosclerosis risk in communities study. Hypertension 2006; 48: 1037-42.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson RJ, Feig DI, Herera-Acosta J et al. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45: 18-20.</mixed-citation><mixed-citation xml:lang="en">Johnson RJ, Feig DI, Herera-Acosta J et al. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45: 18-20.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among man. J Am Soc Nephrol 2007; 18: 287-92.</mixed-citation><mixed-citation xml:lang="en">Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among man. J Am Soc Nephrol 2007; 18: 287-92.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Мухин Н.А., Балкаров И.М., Шоничев Д.Г. и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек. Тер. архив. 1999; 6: 23-7.</mixed-citation><mixed-citation xml:lang="en">Мухин Н.А., Балкаров И.М., Шоничев Д.Г. и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек. Тер. архив. 1999; 6: 23-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Feig DI, Nakagawa T, Karumanchi SA et al. Hypothesis: Uric acid, nephron number and the pathogenesis of essential hypertension. Kidney Int 2004; 66 (1): 281-7.</mixed-citation><mixed-citation xml:lang="en">Feig DI, Nakagawa T, Karumanchi SA et al. Hypothesis: Uric acid, nephron number and the pathogenesis of essential hypertension. Kidney Int 2004; 66 (1): 281-7.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Church WH, Rappolt G. Nigrostriatal catecholamine metabolism in guinea pigs is altered by purine enzyme inhibition. Exp Brain Res 1999; 127: 147-50.</mixed-citation><mixed-citation xml:lang="en">Church WH, Rappolt G. Nigrostriatal catecholamine metabolism in guinea pigs is altered by purine enzyme inhibition. Exp Brain Res 1999; 127: 147-50.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Challet E, Le Macho Y, Robin JP et al. Involvement of corticosterone in the fasting-induced rise in pritein utilization and locomotor activity. Pharmacol Biochem Behav 1995; 50: 405-12.</mixed-citation><mixed-citation xml:lang="en">Challet E, Le Macho Y, Robin JP et al. Involvement of corticosterone in the fasting-induced rise in pritein utilization and locomotor activity. Pharmacol Biochem Behav 1995; 50: 405-12.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hink HU, Santanam N, Dikalov S et al. Peroxidase properties of extracellular superoxidedismutase: role of uric acid in modulating in vivo activity. Arteriosclerosis Thrombosis and Vascular Biology 2002; 22: 1402-8.</mixed-citation><mixed-citation xml:lang="en">Hink HU, Santanam N, Dikalov S et al. Peroxidase properties of extracellular superoxidedismutase: role of uric acid in modulating in vivo activity. Arteriosclerosis Thrombosis and Vascular Biology 2002; 22: 1402-8.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tan S, RadI r, Gaudier F et al. Physiologic levels of uric acid inhibit xanthine oxidase in human plasma. Pediatr Res 1993; 34: 303-7.</mixed-citation><mixed-citation xml:lang="en">Tan S, RadI r, Gaudier F et al. Physiologic levels of uric acid inhibit xanthine oxidase in human plasma. Pediatr Res 1993; 34: 303-7.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Corry DB, Eslami P, Yamamoto K et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertension 2008; 26 (2): 269-75.</mixed-citation><mixed-citation xml:lang="en">Corry DB, Eslami P, Yamamoto K et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertension 2008; 26 (2): 269-75.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sautin YY, Nakagawa T, Zharikov S et al. Adverse effects of the ckassical antioxidant uric acid in adypocites: NAD-PH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: 584-96.</mixed-citation><mixed-citation xml:lang="en">Sautin YY, Nakagawa T, Zharikov S et al. Adverse effects of the ckassical antioxidant uric acid in adypocites: NAD-PH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: 584-96.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kang DK, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxid production of human vascular cells. J Am Soc Nephrology 2005; 16: 3553-62.</mixed-citation><mixed-citation xml:lang="en">Kang DK, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxid production of human vascular cells. J Am Soc Nephrology 2005; 16: 3553-62.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-42.</mixed-citation><mixed-citation xml:lang="en">Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-42.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40 (3): 355-60.</mixed-citation><mixed-citation xml:lang="en">Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40 (3): 355-60.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Carnethon MR, Fortman SP, Palaniappan L et al. Risk factors for progression to incident hyperinsulinemia: the atherosclerosis risk in communiteies study 1987-1998. Am J Epidemiol 2003; 158: 1058-67.</mixed-citation><mixed-citation xml:lang="en">Carnethon MR, Fortman SP, Palaniappan L et al. Risk factors for progression to incident hyperinsulinemia: the atherosclerosis risk in communiteies study 1987-1998. Am J Epidemiol 2003; 158: 1058-67.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Danielson E, Rifai N et al. Valsartan, Blood pressure reduction and C-reactive protein. Hypertension 2006; 48: 1-7.</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Danielson E, Rifai N et al. Valsartan, Blood pressure reduction and C-reactive protein. Hypertension 2006; 48: 1-7.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Paulleto P, Rattazzi M. Inflammation and hypertension: the search for link. Nephrol Dial Transplant 2006; 21: 850-3.</mixed-citation><mixed-citation xml:lang="en">Paulleto P, Rattazzi M. Inflammation and hypertension: the search for link. Nephrol Dial Transplant 2006; 21: 850-3.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kim Chul Sung, Jung Yul Suh, Bum Soo Kim et al. High Sensitivity C-reactive protein an independent risk factor for essential hypertension. Am J Hyperten 2003; 16: 429-33.</mixed-citation><mixed-citation xml:lang="en">Kim Chul Sung, Jung Yul Suh, Bum Soo Kim et al. High Sensitivity C-reactive protein an independent risk factor for essential hypertension. Am J Hyperten 2003; 16: 429-33.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ощепкова Е.В., Дмитриев В.А, Титов В.Н и др. Показатели неспецифичного воспаления у больных гипертонической болезнью. Тер. архив. 2007; 79 (12): 18-25.</mixed-citation><mixed-citation xml:lang="en">Ощепкова Е.В., Дмитриев В.А, Титов В.Н и др. Показатели неспецифичного воспаления у больных гипертонической болезнью. Тер. архив. 2007; 79 (12): 18-25.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Национальные рекомендации по профилактике диагностике и лечению артериальной гипертонии. ВНОК 2004 г., 2-й пересмотр.</mixed-citation><mixed-citation xml:lang="en">Национальные рекомендации по профилактике диагностике и лечению артериальной гипертонии. ВНОК 2004 г., 2-й пересмотр.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Ощепкова Е.В., Чихладзе Н.М. Артериальная гипертония. Принципы диагностики и лечения (пособие для врачей). М., 2005.</mixed-citation><mixed-citation xml:lang="en">Чазова И.Е., Ощепкова Е.В., Чихладзе Н.М. Артериальная гипертония. Принципы диагностики и лечения (пособие для врачей). М., 2005.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Pearson TA, Mensah GA, Wayne Alexander R et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.</mixed-citation><mixed-citation xml:lang="en">Pearson TA, Mensah GA, Wayne Alexander R et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Cockcroft DW, Gault MN. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.</mixed-citation><mixed-citation xml:lang="en">Cockcroft DW, Gault MN. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Conen D, Wietlisbach V, Bovet P et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004; 4: 9.</mixed-citation><mixed-citation xml:lang="en">Conen D, Wietlisbach V, Bovet P et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004; 4: 9.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Culleton BF, Larson MG, Kannel WB et al. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Int Med 1999; 131: 7-13.</mixed-citation><mixed-citation xml:lang="en">Culleton BF, Larson MG, Kannel WB et al. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Int Med 1999; 131: 7-13.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnan E, Kwoh CK, Schumacher HR et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49 (2): 298-303.</mixed-citation><mixed-citation xml:lang="en">Krishnan E, Kwoh CK, Schumacher HR et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49 (2): 298-303.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Niemirska A, Sladowska J, Antoniewicz J et al. Uric acid concentration, metabolic syndrome components and target organ damage in adolescents and adults with essential hypertension. J of Hypertension 2006; 25 (Suppl. 2): s346.</mixed-citation><mixed-citation xml:lang="en">Niemirska A, Sladowska J, Antoniewicz J et al. Uric acid concentration, metabolic syndrome components and target organ damage in adolescents and adults with essential hypertension. J of Hypertension 2006; 25 (Suppl. 2): s346.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson RJ, Sautin Y, Oliver WJ et al. Lessons from comparative physiology:could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol B.</mixed-citation><mixed-citation xml:lang="en">Johnson RJ, Sautin Y, Oliver WJ et al. Lessons from comparative physiology:could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol B.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">McCord JM, Roy RS, Schaffer SW. Free radicals and myocardial ischemia. The role xanthine oxidase. Adv Myocardial 1985; 5: 183-9.</mixed-citation><mixed-citation xml:lang="en">McCord JM, Roy RS, Schaffer SW. Free radicals and myocardial ischemia. The role xanthine oxidase. Adv Myocardial 1985; 5: 183-9.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson RJ, Duk-Hee Kang, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-90.</mixed-citation><mixed-citation xml:lang="en">Johnson RJ, Duk-Hee Kang, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-90.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. Arch Int Med 2004; 164: 1546-51.</mixed-citation><mixed-citation xml:lang="en">Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. Arch Int Med 2004; 164: 1546-51.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Squadrito GL, Cueto R, Splenser AE et al. Reaction of uric acid with peroxyntrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000; 376: 333-7.</mixed-citation><mixed-citation xml:lang="en">Squadrito GL, Cueto R, Splenser AE et al. Reaction of uric acid with peroxyntrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000; 376: 333-7.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Ames BN, Cathcart R, Schwiers E et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78 (11): 6858-62.</mixed-citation><mixed-citation xml:lang="en">Ames BN, Cathcart R, Schwiers E et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78 (11): 6858-62.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clinica Chemica Acta 2002; 317: 1-15.</mixed-citation><mixed-citation xml:lang="en">de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clinica Chemica Acta 2002; 317: 1-15.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Zoccali C, Maio R, Mallamaci F et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466-71.</mixed-citation><mixed-citation xml:lang="en">Zoccali C, Maio R, Mallamaci F et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466-71.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Warning WS, Webb DJ, Maxwell SRJ. Uric acid as a risk factor for cardiovascular disease. QJM 2000; 93: 707-13.</mixed-citation><mixed-citation xml:lang="en">Warning WS, Webb DJ, Maxwell SRJ. Uric acid as a risk factor for cardiovascular disease. QJM 2000; 93: 707-13.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Viazzi F, Parodi D, Leoncini G et al. Serum Uric Acid and Target Organ Damage in Primary Hypertension. Hypertension 2005; 45: 991-6.</mixed-citation><mixed-citation xml:lang="en">Viazzi F, Parodi D, Leoncini G et al. Serum Uric Acid and Target Organ Damage in Primary Hypertension. Hypertension 2005; 45: 991-6.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Martinon F, Burns K, Tschopp J. The inflamasomme: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Moll Cell 2002; 10 (2): 417-26.</mixed-citation><mixed-citation xml:lang="en">Martinon F, Burns K, Tschopp J. The inflamasomme: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Moll Cell 2002; 10 (2): 417-26.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzali M, Hughes J, Kim Yoon-Goo et al. Elevated uric acid increases bloods pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-6.</mixed-citation><mixed-citation xml:lang="en">Mazzali M, Hughes J, Kim Yoon-Goo et al. Elevated uric acid increases bloods pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-6.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson RJ, Rodriguez-Iturbe B, Duk-Hee Kang et al. A unifying pathway for essential hypertension. Am J Hypertens 2005; 18: 431-40.</mixed-citation><mixed-citation xml:lang="en">Johnson RJ, Rodriguez-Iturbe B, Duk-Hee Kang et al. A unifying pathway for essential hypertension. Am J Hypertens 2005; 18: 431-40.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Yasunari K, Maeda K, Nakamura M et al. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose and C-reactive protein. Hypertension 2002; 39: 777-89.</mixed-citation><mixed-citation xml:lang="en">Yasunari K, Maeda K, Nakamura M et al. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose and C-reactive protein. Hypertension 2002; 39: 777-89.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Ruggiero C, Cherubini A, Ble A et al. Uric acid and inflammatory markers. Eur Heart J 2006; 27: 1171-81.</mixed-citation><mixed-citation xml:lang="en">Ruggiero C, Cherubini A, Ble A et al. Uric acid and inflammatory markers. Eur Heart J 2006; 27: 1171-81.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Coutinho TA, Turner ST, Peyser PA et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 2007; 20 (1): 83-9.</mixed-citation><mixed-citation xml:lang="en">Coutinho TA, Turner ST, Peyser PA et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 2007; 20 (1): 83-9.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Feig DI, Duk Hee Kang, Johnson R. Uric acid and cardiovascular risk. NEJM 2008; 359: 1811-21.</mixed-citation><mixed-citation xml:lang="en">Feig DI, Duk Hee Kang, Johnson R. Uric acid and cardiovascular risk. NEJM 2008; 359: 1811-21.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
